To further investigate whether inhibiting CD63+ CAF activity could sensitize breast tumors to tamoxifen therapy, we intraperitoneally administered anti‐CD63 neutralizing monoclonal antibody to tumor‐bearing mice, and the results showed that it significantly enhanced the effectiveness of tamoxifen treatment (Figure 8A). The gene discussed is CD63; the disease is breast neoplasm.